An investigation on behalf of investors in Advaxis, Inc. (NASDAQ:ADXS) shares over potential wrongdoing at Advaxis, was announced and NASDAQ:ADXS stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 06/15/2017 --An investigation was announced for investors in shares of Advaxis, Inc. (NASDAQ:ADXS) was announced over potential breaches of fiduciary duties by certain directors.

Investors who purchased shares of Advaxis, Inc. (NASDAQ:ADXS) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm concerns whether certain Advaxis, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

Princeton, NJ based Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. Advaxis, Inc. reported that its Net Loss increased from $47.03 million for the 12months period that ended on Octboer 31, 2015 to $3.99 million for the 12 months period that ended on October 31, 2016.

On June 14, 2017, NASDAQ:ADXS shares closed at $6.77 per share.

Those who purchased shares of Advaxis, Inc. have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com